GlycoEra is developing biologics that selectively target autoantibodies associated with many autoimmune diseases.
Its approach is intended to degrade targets while avoiding broader suppression of the immune system.
Based on the company’s public LinkedIn information, supplied through RevenueBase.
The BiND platform is described as targeting circulating proteins across therapeutic areas, including autoantibodies, inflammation-inducing factors and protein aggregates.
Source: LinkedIn company description · Retrieved October 13, 2026
Supported appearances on published RevenueBase lists, including available memberships beyond displayed rankings.
Positions describe ordering within each source list. See how lists are built ↗
Embeddable award for your website
Open the published source list.RevenueBase prepared this profile from the company’s public LinkedIn information and RevenueBase company data. These source records were retrieved on October 13, 2026. AI helped summarize these sources, with a separate automated check against the source text completed on November 3, 2026. Directory positions use company-contact counts from separate saved list snapshots dated September 19, 2026. How the company lists are built.
Share a correction, your relationship to the company, and supporting sources. Requests are reviewed before changes are published.
Explore more companies by name, headquarters and business focus.